Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect of Evacetrapib in Healthy Japanese Subjects
NCT02226653Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of evacetrapib in dyslipidemia and hypercholesterolemia (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Curve From Zero to Infinity (Fasted) at 168 hours and Maximum Concentration (Fasted) at 168 hours. Started Sep 2014; status: completed.
02
Drugs
evacetrapib
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT02226653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226653.